Abstract: A non-human animal model for screening potential agents for the treatment of diseases relating from changes in glucose homeostasis, such as diabetes and other metabolic diseases such as obesity is disclosed. The invention also relates to associated polynucleotide constructs, vectors, cells and methods for testing and screening such potential drugs.

Abstract: A method for the treatment of conditions associated with a need for inhibition of GSK-3, such as diabetes, dementias such as Alzheimer's disease and manic depression which method comprises the administration of a pharmaceutically effective, non-toxic amount of a compound of formula (I): or a pharmaceutically acceptable derivative thereof, wherein: R is hydrogen, alkyl, aryl, or aralkyl; R1 is hydrogen, alkyl, aralkyl, hydroxyalkyl or alkoxyalkyl; R2 is substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl; R3 is hydrogen, substituted or unsubstituted alkyl, cycloalkyl, alkoxyalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl or aralkyl wherein the aryl moiety is substituted or unsubstituted; or, R1 and R3 together with the nitrogen to which they are attached form a single or fused, optionally substituted, saturated or unsaturated heterocylic ring; to a human or non-human mammal in need thereof, and compounds of formula I.

Abstract: A method for the treatment of conditions associated with a need for inhibition of GSK-3, such as diabetes, dementias such as Alzheimer's disease and manic depression which method comprises the administration of a pharmaceutically effective, non-toxic amount of a compound of formula (I): 1

Abstract: The use of NOT1 or NOT1 a polypeptides and polynucleotides in the design of protocols for the treatment of obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia or liposarcoma among others, and diagnostic assays for such conditions.